Skip to content
Screener

Arcus Biosciences RCUS Q1 2025 earnings

Reported May 6, 2025 · After market close

Revenue$28.0MMiss by $9.4M
EPS-$1.14Miss by $0.12
Revenue estimate$37.4M
EPS estimate-$1.02

Next report

Oct 27, 2026 (in a month)
Revenue estimate$11.0M
EPS estimate-$0.89

Financials

Q1 2025

Income statement

See full
Revenue$28.0M-80.7%
Operating income-$122.0M-663%
Net income-$112.0M-2,700%
EPS (diluted)-$1.14-2,180%

Balance sheet

See full
Cash & equivalents$192.0M+3.8%
Total debt$60.0M+445%
Total equity$531.0M-24.9%
Total assets$1.2B-10.6%

Cash flow

See full
Operating cash flow-$132.0M-6,500%
CapEx$1.0M-75.0%
Free cash flow-$133.0M-2,117%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$830.86M-48.9%
Enterprise value$698.86M-51.9%
P/S5.9×-1.0×

Profitability

See full
Operating margin-309.2%-742pp
Net margin-277.3%-605pp

Returns & leverage

See full
Return on equity-63.2%+233pp
Debt / equity0.1×+0.1×
Current ratio5.4×+0.2×

Segments

By segment

See full
Reportable segment$28.0M-80.7%

By product

See full
R&D services$2.0M—

FAQ

When did Arcus Biosciences report Q1 2025 earnings?
Arcus Biosciences (RCUS) reported Q1 2025 earnings on May 6, 2025 after market close.
What were Arcus Biosciences's Q1 2025 revenue and EPS?
Arcus Biosciences reported revenue of $28.0M and eps of $-1.14 for Q1 2025.
Did Arcus Biosciences beat estimates in Q1 2025?
Revenue missed the consensus estimate of $37.4M by $9.4M. EPS missed the consensus estimate of $-1.02 by $0.12.
How did Arcus Biosciences's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 80.7% from $145.0M a year earlier and eps declined 2180.0% from $-0.05.
Where can I find Arcus Biosciences's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001724521-25-000061) and the 10-Q periodic report (0001724521-25-000063) directly on SEC EDGAR. The filing index links above go to sec.gov.